AR075898A1 - Derivados de amida como ligandos del receptor y5 del neuropeptido. - Google Patents
Derivados de amida como ligandos del receptor y5 del neuropeptido.Info
- Publication number
- AR075898A1 AR075898A1 ARP100100893A ARP100100893A AR075898A1 AR 075898 A1 AR075898 A1 AR 075898A1 AR P100100893 A ARP100100893 A AR P100100893A AR P100100893 A ARP100100893 A AR P100100893A AR 075898 A1 AR075898 A1 AR 075898A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- phenyl
- neuropeptide
- perfluoroalkyl
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 abstract 1
- 102000012301 Neuropeptide Y receptor Human genes 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- LBFSHXXTLRZXST-UHFFFAOYSA-N pyridazine;pyrimidine Chemical compound C1=CC=NN=C1.C1=CN=CN=C1 LBFSHXXTLRZXST-UHFFFAOYSA-N 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003852 triazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describe una serie de ligandos del receptor Y5 del neuropéptido Y, y como tales son utiles para tratar trastornos relacionados con el ánimo, estrés, ADHD, cognicion y demencia. Composicion farmacéutica y usos. Reivindicacion 1: Un compuesto de formula (1) donde R1 es alquilo C1-7, perfluoroalquilo C1-7, alcoxi C1-7 o halogeno; donde R2 es alquilo C1-7; donde R3 es H, alquilo C1-7, alcoxi C1-7, -(CH2)uOH, -N(R4)C(O)alquilo C1-7 o -N(R4)C(O)alcoxi C1-7; donde R4 es H o alquilo C1-7; donde X es -CH2-, -O-, -CH2O-, -NR5- o -CH2NR5-; donde R5 es H, alquilo C1-7, fenilo o piridilo, donde el fenilo y piridilo son opcionalmente sustituidos con alquilo C1-7, perfluoroalquilo C1-7, alcoxi C1-7 o halogeno; donde Ar es una porcion aromática divalente seleccionada del grupo formado por fenilo, piridina, pirimidina piridazina, pirazina, imidazol, pirazol, triazol, oxazol e isoxazol; donde cada m y n es independientemente un numero entero de 0 a 5 inclusive; donde u es 0 o 1; y donde cada t y s es independientemente un numero entero de 0 a 2 inclusive; o su sal farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16180209P | 2009-03-20 | 2009-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075898A1 true AR075898A1 (es) | 2011-05-04 |
Family
ID=42740244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100893A AR075898A1 (es) | 2009-03-20 | 2010-03-19 | Derivados de amida como ligandos del receptor y5 del neuropeptido. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20120101078A1 (es) |
| EP (1) | EP2408767B1 (es) |
| JP (1) | JP2012521350A (es) |
| KR (1) | KR20110136818A (es) |
| CN (1) | CN102356079A (es) |
| AR (1) | AR075898A1 (es) |
| AU (1) | AU2010226553B2 (es) |
| BR (1) | BRPI1014526A2 (es) |
| CA (1) | CA2756003A1 (es) |
| CL (1) | CL2011002319A1 (es) |
| CO (1) | CO6430464A2 (es) |
| EA (1) | EA201171149A1 (es) |
| IL (1) | IL215226A0 (es) |
| MX (1) | MX2011009886A (es) |
| NZ (1) | NZ595265A (es) |
| SG (1) | SG174472A1 (es) |
| TW (1) | TW201103907A (es) |
| WO (1) | WO2010108052A2 (es) |
| ZA (1) | ZA201106812B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9968574B2 (en) | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| WO2011142778A1 (en) * | 2010-05-13 | 2011-11-17 | The University Of Kentucky Research Foundation | Treatment of mci and alzheimer's disease |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399631B1 (en) * | 1999-07-23 | 2002-06-04 | Pfizer Inc. | Carbazole neuropeptide Y5 antagonists |
| AR030676A1 (es) * | 1999-07-28 | 2003-09-03 | Ortho Mcneil Pharm Inc | Derivados de aminas y amidas como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de la obesidad y otros trastornos, uso de los mismos para la elaboracion de medicamentos y composiciones farmaceuticas que los comprenden |
| WO2004089919A1 (ja) * | 2003-04-02 | 2004-10-21 | Banyu Pharmaceutical Co., Ltd. | シクロヘキサンカルボキサミド誘導体 |
| JP2006298909A (ja) * | 2005-03-25 | 2006-11-02 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
-
2010
- 2010-03-18 TW TW099107952A patent/TW201103907A/zh unknown
- 2010-03-19 EP EP10754142.7A patent/EP2408767B1/en active Active
- 2010-03-19 EA EA201171149A patent/EA201171149A1/ru unknown
- 2010-03-19 SG SG2011067741A patent/SG174472A1/en unknown
- 2010-03-19 MX MX2011009886A patent/MX2011009886A/es active IP Right Grant
- 2010-03-19 CN CN2010800135437A patent/CN102356079A/zh active Pending
- 2010-03-19 US US13/256,981 patent/US20120101078A1/en not_active Abandoned
- 2010-03-19 JP JP2012500981A patent/JP2012521350A/ja active Pending
- 2010-03-19 AR ARP100100893A patent/AR075898A1/es not_active Application Discontinuation
- 2010-03-19 NZ NZ595265A patent/NZ595265A/xx not_active IP Right Cessation
- 2010-03-19 AU AU2010226553A patent/AU2010226553B2/en not_active Ceased
- 2010-03-19 KR KR1020117021983A patent/KR20110136818A/ko not_active Application Discontinuation
- 2010-03-19 WO PCT/US2010/027892 patent/WO2010108052A2/en active Application Filing
- 2010-03-19 BR BRPI1014526A patent/BRPI1014526A2/pt not_active IP Right Cessation
- 2010-03-19 CA CA2756003A patent/CA2756003A1/en not_active Abandoned
-
2011
- 2011-09-19 IL IL215226A patent/IL215226A0/en unknown
- 2011-09-19 ZA ZA2011/06812A patent/ZA201106812B/en unknown
- 2011-09-19 CO CO11121403A patent/CO6430464A2/es not_active Application Discontinuation
- 2011-09-20 CL CL2011002319A patent/CL2011002319A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL215226A0 (en) | 2011-12-29 |
| JP2012521350A (ja) | 2012-09-13 |
| CL2011002319A1 (es) | 2012-08-31 |
| AU2010226553A1 (en) | 2011-10-13 |
| ZA201106812B (en) | 2012-11-28 |
| CA2756003A1 (en) | 2010-09-23 |
| CO6430464A2 (es) | 2012-04-30 |
| WO2010108052A3 (en) | 2011-02-24 |
| CN102356079A (zh) | 2012-02-15 |
| SG174472A1 (en) | 2011-10-28 |
| NZ595265A (en) | 2013-02-22 |
| TW201103907A (en) | 2011-02-01 |
| BRPI1014526A2 (pt) | 2016-04-05 |
| AU2010226553B2 (en) | 2012-05-31 |
| WO2010108052A2 (en) | 2010-09-23 |
| US20120101078A1 (en) | 2012-04-26 |
| EP2408767A4 (en) | 2012-08-22 |
| EA201171149A1 (ru) | 2012-03-30 |
| EP2408767B1 (en) | 2013-07-10 |
| MX2011009886A (es) | 2011-09-30 |
| KR20110136818A (ko) | 2011-12-21 |
| EP2408767A2 (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017279570B2 (en) | Trk-inhibiting compound | |
| ES2605388T3 (es) | Compuesto inhibidor de Trk | |
| JP6322205B2 (ja) | がん治療用のピリミジン−２，４−ジアミン誘導体 | |
| JP2018024670A (ja) | キナーゼ活性の阻害剤 | |
| JP5615902B2 (ja) | イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体 | |
| NO20092415L (no) | Heteromonocyklisk forbindelse og anvendelse derav | |
| AR104716A1 (es) | Agonistas de triazol del receptor apj | |
| MY148434A (en) | Fused bicyclic heteroaryl derivatives | |
| WO2008115098A3 (fr) | 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation | |
| MX2011005096A (es) | Derivados de azaquinolinona y usos de los mismos. | |
| AR059056A1 (es) | Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia | |
| JP2018526419A5 (es) | ||
| CA2971357A1 (en) | Amido thiadiazole derivatives as nadph oxidase inhibitors | |
| WO2008078837A1 (en) | 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhbitors | |
| EP2844656A1 (en) | Substituted pyrazole compounds as crac modulators | |
| AR075898A1 (es) | Derivados de amida como ligandos del receptor y5 del neuropeptido. | |
| AR102825A1 (es) | Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre | |
| WO2019054430A1 (ja) | 芳香族複素環を有するアミド化合物 | |
| PE20081371A1 (es) | Derivados de acido 2-fenoxinicotinico como moduladores de ppar-alfa | |
| NZ735032A (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | |
| PH12018500247A1 (en) | Ethynyl derivatives | |
| UA110343C2 (en) | Spiro heterocyclic compounds as antagonists mglur5 | |
| BRPI0918966B8 (pt) | composto inibidor de protease, composição farmacêutica compreendendo dito composto e uso terapêutico do mesmo | |
| BRPI0714615A2 (pt) | Éteres heterocÍclicos substituÍdos e sua utilizaÇço em distérbios do cns | |
| WO2020143385A1 (zh) | 芳基酰胺类抑制剂及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |